logo
NasdaqCM:GOVX logo

GeoVax Labs Community

NasdaqCM:GOVX Community
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 11 Fair Values set on narratives written by author
Create a narrative

Community Investing Ideas

GOVX logo
GeoVax Labs
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts

Gedeptin And GEO-MVA Trials Will Shape Vaccine And Cancer Pipelines

Key Takeaways Progress in vaccines and strategic partnerships could drive revenue growth from commercialization and global stockpile opportunities. Cost advantages in manufacturing and exploration of funding options may enhance financial stability and improve net margins.
View narrative
US$10.70
FV
91.3% undervalued intrinsic discount
246.26%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
4 days ago author updated this narrative